Antitumor drug. Letrozole has an anti-estrogenic effect, selectively inhibits aromatase (an enzyme for the synthesis of estrogens) by highly specific competitive binding to the subunit of this enzyme - the cytochrome P450 heme. Blocks the synthesis of estrogens in both peripheral and tumor tissues.
In postmenopausal women, estrogens are formed mainly with the participation of the aromatase enzyme, which converts androgens synthesized in the adrenal glands (primarily androstenedione and testosterone) into estrone and estradiol.Blocking the biosynthesis of estrogens does not lead to the accumulation of androgens, which are the precursors of estrogens. There were no changes in the content of LH and FSH in blood plasma, changes in thyroid function, changes in the lipid profile, as well as an increase in the frequency of myocardial infarction and stroke.
- Breast cancer at an early stage, cells which are hormone receptors in women in the postmenopausal women as adjuvant therapy
- early stage of breast cancer in postmenopausal women after completion of standard adjuvant therapy with tamoxifen as extended adjuvant therapy
- common hormone-dependent forms of breast cancer in postmenopausal women (first-line therapy)
- common forms of breast cancer in postmenopausal women (natural or artificially induced) who had previously received anti-estrogen therapy.
- The drug is taken orally, regardless of food intake.They are prescribed for adults. The recommended dose of Letrose is 2.5 mg 1 time/day, daily, for a long time.
- As an extended adjuvant therapy, treatment should be continued for 5 years (no more than 5 years)
|Active ingredient, mg||2,5|
|1 pill, mg||2,5|
|Blister, pills||2, 50|
|Packing||Packing (2 blisters), Blister (50 pills)|